好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of Depression and Anxiety on Migraine-Related Disability: Results from the Headache Assessment via Digital Platform in the United States (HeAD-US) Study
Headache
P5 - Poster Session 5 (8:00 AM-9:00 AM)
12-002

To assess the relationship between anxiety and depressive symptoms on headache-related disability in individuals with migraine in a real-world study.
Though symptoms of anxiety and depression are common in migraine, their association with disability is poorly characterized in real world studies. 
We used cross-sectional data from 6267 participants with migraine recruited using the Migraine Buddy app to create the Headache Assessment via Digital Platform in the United States (HeAD-US) registry. Migraine disability was assessed using the Migraine Disability Assessment Scale (MIDAS). Anxiety and depressive symptoms were evaluated using the 4-item Personal Health Questionnaire (PHQ-4). Participants were categorized into four subgroups: anxiety symptoms only, depressive symptoms only, both, or neither. Negative binomial regression was used to explore associations between subgroups and migraine disability.
Participants were 41.5±13 years old on average, 90.8% were women, and 84.6% were white. 37.4% had chronic migraine (CM) while 62.6% had episodic migraine (EM). 91.5% had MIDAS scores of 11 or greater (moderate and severe disability).18.7% had anxiety symptoms only, 6.1% had depressive symptoms only, 23.8% had both, and 51.4% had neither. Coexisting anxiety and depressive symptoms were more common in CM than in EM (30.3% vs 20.0%; p<0.001) as were depressive symptoms alone (8.0% vs 4.9%; p<0.001). Differences in anxiety symptoms alone were not significant. Anxiety symptoms alone and depressive symptoms alone were associated with 8.7% (rr=1.087) and 28.4% (rr=1.284) increase in MIDAS score, respectively (both p<0.001). Coexisting anxiety and depression were associated with a 32.5% increase (rr=1.325, p<0.001) in MIDAS score.

Symptoms of anxiety and depression are more common in CM than EM and associated with greater migraine disability separately and jointly. This real-world study extends findings from population and clinic-based studies.
Authors/Disclosures
Adalmina Sarkar
PRESENTER 		Ms. Sarkar has nothing to disclose.
Elham Ghanbarian, MD, PhD Dr. Ghanbarian has nothing to disclose.
Babak Khorsand, PhD Dr. Khorsand has nothing to disclose.
Kristina M. Fanning, PhD (MIST Reserach) The institution of Dr. Fanning has received research support from Abbvie. The institution of Dr. Fanning has received research support from NYC Langone Health . The institution of Dr. Fanning has received research support from Uiversity of SC - Irvine. The institution of Dr. Fanning has received research support from AESARA.
Alexandre Urani (Healint) Alexandre Urani has received personal compensation for serving as an employee of Aptar Digital Health.
Francois Cadiou, MBA (Healint) Mr. Cadiou has received personal compensation for serving as an employee of Healint.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
Ali Ezzati, MD (University of California, Irvine) The institution of Dr. Ezzati has received research support from NIA. The institution of Dr. Ezzati has received research support from Alzheimer's Association. The institution of Dr. Ezzati has received research support from Cure Alzheimer's Fund.